152 related articles for article (PubMed ID: 37643144)
1. Beyond fluconazole: A review of vulvovaginal candidiasis diagnosis and treatment.
Hellier SD; Wrynn AF
Nurse Pract; 2023 Sep; 48(9):33-39. PubMed ID: 37643144
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Kan S; Song N; Pang Q; Mei H; Zheng H; Li D; Cui F; Lv G; An R; Li P; Xiong Z; Fan S; Zhang M; Chen Y; Qiao Q; Liang X; Cui M; Li D; Liao Q; Li X; Liu W
Mycopathologia; 2023 Apr; 188(1-2):99-109. PubMed ID: 36378354
[TBL] [Abstract][Full Text] [Related]
3. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Phillips NA; Rocktashel M; Merjanian L
Drug Des Devel Ther; 2023; 17():363-367. PubMed ID: 36785761
[TBL] [Abstract][Full Text] [Related]
4. Treatment of vulvovaginal candidiasis: a review of the literature.
Dovnik A; Golle A; Novak D; Arko D; Takač I
Acta Dermatovenerol Alp Pannonica Adriat; 2015; 24(1):5-7. PubMed ID: 25770305
[TBL] [Abstract][Full Text] [Related]
5. Possible misdiagnosis, inappropriate empiric treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis-United States, 2018.
Benedict K; Lyman M; Jackson BR
PLoS One; 2022; 17(4):e0267866. PubMed ID: 35482794
[TBL] [Abstract][Full Text] [Related]
6. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
7. Recurrent vulvovaginal candidiasis.
Blostein F; Levin-Sparenberg E; Wagner J; Foxman B
Ann Epidemiol; 2017 Sep; 27(9):575-582.e3. PubMed ID: 28927765
[TBL] [Abstract][Full Text] [Related]
8. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes.
Yano J; Sobel JD; Nyirjesy P; Sobel R; Williams VL; Yu Q; Noverr MC; Fidel PL
BMC Womens Health; 2019 Mar; 19(1):48. PubMed ID: 30925872
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
Waikhom SD; Afeke I; Kwawu GS; Mbroh HK; Osei GY; Louis B; Deku JG; Kasu ES; Mensah P; Agede CY; Dodoo C; Asiamah EA; Tampuori J; Korbuvi J; Opintan JA
BMC Pregnancy Childbirth; 2020 May; 20(1):266. PubMed ID: 32375724
[TBL] [Abstract][Full Text] [Related]
10. Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis.
Ge G; Yang Z; Li D; Zhang N; Chen B; Shi D
Front Immunol; 2022; 13():959740. PubMed ID: 35967437
[TBL] [Abstract][Full Text] [Related]
11. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol.
Lírio J; Giraldo PC; Amaral RL; Sarmento ACA; Costa APF; Gonçalves AK
BMJ Open; 2019 May; 9(5):e027489. PubMed ID: 31122991
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
Ray D; Goswami R; Banerjee U; Dadhwal V; Goswami D; Mandal P; Sreenivas V; Kochupillai N
Diabetes Care; 2007 Feb; 30(2):312-7. PubMed ID: 17259500
[TBL] [Abstract][Full Text] [Related]
13. Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.
Collins LM; Moore R; Sobel JD
J Low Genit Tract Dis; 2020 Jan; 24(1):48-52. PubMed ID: 31860575
[TBL] [Abstract][Full Text] [Related]
14. Vaginal pH and microbiota during fluconazole maintenance treatment for recurrent vulvovaginal candidosis (RVVC).
Donders GG; Grinceviciene S; Ruban K; Bellen G
Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115024. PubMed ID: 32253071
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.
Garvey EP; Hoekstra WJ; Schotzinger RJ; Sobel JD; Lilly EA; Fidel PL
Antimicrob Agents Chemother; 2015 Sep; 59(9):5567-73. PubMed ID: 26124165
[TBL] [Abstract][Full Text] [Related]
16. Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review.
Bradfield Strydom M; Khan S; Walpola RL; Ware RS; Tiralongo E
J Med Microbiol; 2023 May; 72(5):. PubMed ID: 37171871
[TBL] [Abstract][Full Text] [Related]
17. [Genital candidiasis].
Ono F; Yasumoto S
Nihon Rinsho; 2009 Jan; 67(1):157-61. PubMed ID: 19177766
[TBL] [Abstract][Full Text] [Related]
18. Recurrent vulvovaginal candidiasis.
Sobel JD
Am J Obstet Gynecol; 2016 Jan; 214(1):15-21. PubMed ID: 26164695
[TBL] [Abstract][Full Text] [Related]
19. Vulvovaginal candidiasis in Iranian women: Molecular identification and antifungal susceptibility pattern.
Khaksar Baniasadi A; Ayatollahi Mosavi SA; Sharifi I; Bamorovat M; Salari S; Ahmadi A; Amanizadeh A; Agha Kuchak Afshari S
J Obstet Gynaecol Res; 2022 Dec; 48(12):3292-3303. PubMed ID: 36184563
[TBL] [Abstract][Full Text] [Related]
20. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis.
Fan S; Liu X; Wu C; Xu L; Li J
Mycopathologia; 2015 Feb; 179(1-2):95-101. PubMed ID: 25416649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
